Document is current
Any future updates will be listed below
-
Authors
Ali, Muhammad https://orcid.org/0000-0001-8964-4416
Giannakopoulou, Eirini
Li, Yingqian
Lehander, Madeleine
Virding Culleton, Stina
Yang, Weiwen
Knetter, Cathrine
Odabasi, Mete Can
Bollineni, Ravi Chand
Yang, Xinbo
Foldvari, Zsofia
Böschen, Maxi-Lu
Taraldsrud, Eli
Strønen, Erlend https://orcid.org/0000-0001-9314-9389
Toebes, Mireille
Hillen, Amy
Mazzi, Stefania
de Ru, Arnoud H.
Janssen, George M. C.
Kolstad, Arne
Tjønnfjord, Geir Erland
Lie, Benedicte A.
Griffioen, Marieke https://orcid.org/0000-0002-3001-4441
Lehmann, Sören
Osnes, Liv Toril
Buechner, Jochen https://orcid.org/0000-0001-5848-4501
Garcia, K. Christopher https://orcid.org/0000-0001-9273-0278
Schumacher, Ton N. https://orcid.org/0000-0003-0517-8804
van Veelen, Peter A.
Leisegang, Matthias https://orcid.org/0000-0003-3692-7142
Jacobsen, Sten Eirik W.
Woll, Petter https://orcid.org/0000-0002-2340-2526
Olweus, Johanna https://orcid.org/0000-0002-1898-3100
- License Information
-
More Information
Article History
Received: 25 March 2021
Accepted: 2 September 2021
First Online: 6 December 2021
Competing interests
: J.O. has a research collaboration with Kite Pharma/Gilead, Inc., and a patent application by the institutional technology transfer office Inven2 was filed (patent application number 2113437.4) that covers TCR receptor sequences (inventors J.O. and M.A.). T.N.S. is a consultant for Adaptive Biotechnologies, AIMM Therapeutics, Allogene Therapeutics, Merus, Neogene Therapeutics, Neon Therapeutics and Scenic Biotech; is a recipient of grant/research support from MSD, Bristol-Myers Squibb and Merck KGaA; is a stockholder in AIMM Therapeutics, Allogene Therapeutics, Merus, Neogene Therapeutics and Neon Therapeutics; and is venture partner at Third Rock Ventures. G.E.T. has received research support from Mundipharma and lecture honoraria from Mundipharma, Abbvie, Janssen-Cilag, Alexion Pharmaceuticals and Roche Norway. The remaining authors declare no competing interests.
